CN112294963A - Pharmaceutical composition for treating age-related macular degeneration - Google Patents
Pharmaceutical composition for treating age-related macular degeneration Download PDFInfo
- Publication number
- CN112294963A CN112294963A CN201910698934.XA CN201910698934A CN112294963A CN 112294963 A CN112294963 A CN 112294963A CN 201910698934 A CN201910698934 A CN 201910698934A CN 112294963 A CN112294963 A CN 112294963A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- pharmaceutical composition
- fructus
- composition comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 138
- 206010064930 age-related macular degeneration Diseases 0.000 title claims description 34
- 208000002780 macular degeneration Diseases 0.000 title claims description 34
- 235000003713 Rhodiola rosea Nutrition 0.000 claims abstract description 41
- 244000042430 Rhodiola rosea Species 0.000 claims abstract description 41
- 241000270666 Testudines Species 0.000 claims abstract description 39
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 33
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 29
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 29
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 19
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 19
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 3
- 235000011477 liquorice Nutrition 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 57
- 210000000582 semen Anatomy 0.000 claims description 39
- 229940079593 drug Drugs 0.000 claims description 31
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims description 16
- 244000236658 Paeonia lactiflora Species 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 229940030225 antihemorrhagics Drugs 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 12
- 239000002874 hemostatic agent Substances 0.000 claims description 12
- 230000002439 hemostatic effect Effects 0.000 claims description 12
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 9
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 9
- 229940010454 licorice Drugs 0.000 claims description 9
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 208000026435 phlegm Diseases 0.000 claims description 8
- 241000628997 Flos Species 0.000 claims description 6
- 206010030113 Oedema Diseases 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 235000015961 tonic Nutrition 0.000 claims description 6
- 230000001256 tonic effect Effects 0.000 claims description 6
- 229960000716 tonics Drugs 0.000 claims description 6
- 238000010792 warming Methods 0.000 claims description 6
- 208000004880 Polyuria Diseases 0.000 claims description 5
- 230000035619 diuresis Effects 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 244000131316 Panax pseudoginseng Species 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- 244000025254 Cannabis sativa Species 0.000 claims description 3
- 241000756943 Codonopsis Species 0.000 claims description 3
- 240000001008 Dimocarpus longan Species 0.000 claims description 3
- 235000000235 Euphoria longan Nutrition 0.000 claims description 3
- 241001243091 Gryllotalpa Species 0.000 claims description 3
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims description 3
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims description 3
- 240000008669 Hedera helix Species 0.000 claims description 3
- 235000003935 Hippophae Nutrition 0.000 claims description 3
- 241000229143 Hippophae Species 0.000 claims description 3
- 241001598107 Imperata Species 0.000 claims description 3
- 244000303847 Lagenaria vulgaris Species 0.000 claims description 3
- 235000009797 Lagenaria vulgaris Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 241000180649 Panax notoginseng Species 0.000 claims description 3
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 3
- 241000222640 Polyporus Species 0.000 claims description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 3
- 241000220261 Sinapis Species 0.000 claims description 3
- 241000244155 Taenia Species 0.000 claims description 3
- 241001506047 Tremella Species 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 108010052008 colla corii asini Proteins 0.000 claims description 3
- 239000004833 fish glue Substances 0.000 claims description 3
- 235000008434 ginseng Nutrition 0.000 claims description 3
- 229940056582 human hair preparation Drugs 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 238000005325 percolation Methods 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- 235000008216 herbs Nutrition 0.000 claims 2
- 241000555682 Forsythia x intermedia Species 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 208000011325 dry age related macular degeneration Diseases 0.000 abstract description 23
- 230000004438 eyesight Effects 0.000 abstract description 19
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract description 16
- 230000002829 reductive effect Effects 0.000 abstract description 11
- 241000576429 Forsythia suspensa Species 0.000 abstract description 6
- 208000000208 Wet Macular Degeneration Diseases 0.000 abstract description 5
- 241000405414 Rehmannia Species 0.000 abstract description 3
- 230000002250 progressing effect Effects 0.000 abstract description 2
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 72
- 230000000694 effects Effects 0.000 description 19
- 235000017443 Hedysarum boreale Nutrition 0.000 description 17
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 17
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 17
- 241001106477 Paeoniaceae Species 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000555712 Forsythia Species 0.000 description 9
- 230000000007 visual effect Effects 0.000 description 9
- 201000004569 Blindness Diseases 0.000 description 8
- 238000012014 optical coherence tomography Methods 0.000 description 8
- 238000009835 boiling Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010003694 Atrophy Diseases 0.000 description 5
- 206010047513 Vision blurred Diseases 0.000 description 5
- 230000037444 atrophy Effects 0.000 description 5
- 230000004393 visual impairment Effects 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 4
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 208000032436 Retinal depigmentation Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000000608 photoreceptor cell Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000004304 visual acuity Effects 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241000209020 Cornus Species 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 230000009978 visual deterioration Effects 0.000 description 2
- 241000213006 Angelica dahurica Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000935235 Fritillaria meleagris Species 0.000 description 1
- 208000008069 Geographic Atrophy Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 240000002624 Mespilus germanica Species 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 201000010183 Papilledema Diseases 0.000 description 1
- 206010033712 Papilloedema Diseases 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000029091 Refraction disease Diseases 0.000 description 1
- 208000002367 Retinal Perforations Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000019631 acid taste sensations Nutrition 0.000 description 1
- 239000002582 adenosine A1 receptor agonist Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004430 ametropia Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009539 direct ophthalmoscopy Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000873 fovea centralis Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000004402 high myopia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000029233 macular holes Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 238000010831 paired-sample T-test Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000001927 retinal artery Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004412 visual outcomes Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a pharmaceutical composition for treating dry AMD, which comprises turtle shells and/or rhodiola rosea, rehmannia roots and/or coix seeds, white paeony roots, weeping forsythia and/or cassia seeds, and liquorice. The pharmaceutical composition can prevent the vision of patients from being reduced, prevent dry AMD from progressing to wet AMD, and can be used as an effective means for preventing and treating dry AMD.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a pharmaceutical composition for treating age-related macular degeneration, which comprises turtle shells and/or rhodiola rosea, can also comprise radix rehmanniae and/or coix seeds, can also comprise white paeony roots, fructus forsythiae and/or semen cassiae, and can also comprise liquorice.
Background
Age-related macular degeneration (AMD) is one of the intractable fundus diseases, and is also one of the leading causes of blindness in the elderly population worldwide, affecting approximately 3000 thousands of people worldwide. Approximately 50% of vision loss and blindness in developed countries can be attributed to AMD, which by 2020 will reach an epidemic level of 300 million people, and epidemiological data show that as the Chinese population ages, the incidence of AMD increases year by year. A survey of AMD morbidity in people over 60 years old from Shanghai city shows that AMD has a diagnosis rate of 13.36%, 6.23% between 60 and 69 years old, 14.98% between 70 and 79 years old and 29.91% above 80 years old, and the morbidity in some areas is even close to the level of foreign developed countries. The literature, Global prediction of age-related macromolecular degeneration, Lancet Global Health, 2014, discloses that from 1990 to 2010, the need to develop a prophylactic or significantly effective treatment remains urgent due to the increased prevalence of macular degeneration, blindness and visual impairment.
AMD clinically involves two major types: collapsed (dry) AMD and exudative (wet) AMD. Dry AMD progresses slowly, with principal manifestations of drusen, atrophy of the Retinal Pigment Epithelium (RPE) and photoreceptor cells, with functional disturbances and degenerative changes of the macula, also severely affecting the quality of life of patients. Dry AMD occurs in high frequency, usually slowly progressing, but is likely to progress to a more severe form, wet AMD, leading to more severe central vision loss, and american AREDS studies indicate that some patients with advanced dry AMD may also develop choroidal neovascularization, transitioning from dry AMD to wet AMD, thus preventing or treating AMD early in time, and reducing or delaying vision loss. At present, no specific medicine is used in western medicine for dry AMD, and only part of medicines are in the development process, such as: patent CN107406479A discloses compounds comprising selective adenosine a1 agonists for the treatment, alleviation or prevention of age-related macular degeneration. However, more are interventions mainly based on the supplementation of antioxidant vitamins and minerals, such as: patent CN101262855A discloses a method for treating and/or preventing age-related macular degeneration, comprising providing an effective amount of carotenoid and/or vitamin C, vitamin E, beta-carotene, zinc and/or copper, and/or mixtures thereof to a subject. The literature 'Chinese age-related macular degeneration clinical diagnosis and treatment path' explains that age-related macular degeneration is treated by antioxidant vitamins and minerals, laser photocoagulation and anti-VEGF. However, there is no clear evidence to support these drugs for treatment of AMD before the intermediate stage.
The traditional Chinese medicine is a great medical treasure house in China, has special curative effect on complex diseases, and provides a new direction for exploring treatment of AMD. Traditional Chinese medicine has a recognition on AMD early, AMD belongs to degenerative disease, and states that essence, qi and blood are in a degenerative and deficiency state after people live through age 40 in the book Huangdi's classic; the dysfunction of the liver, spleen and kidney will further hinder the transportation, transformation and excretion of water, and thus form pathological products such as water, dampness and phlegm. According to the clinical manifestations, it is mostly categorized into "straight looking like curved", "blurred vision", "abnormal viscus", "sudden blindness", etc. A great deal of literature, including ancient Chinese medical books and modern research, shows the success of traditional Chinese medicine in treating dry AMD. For example: patent CN106924655A discloses a preparation method of a Chinese medicinal composition for treating age-related macular degeneration, which comprises extracting thunberg fritillary bulb, Chinese angelica, turmeric root-tuber with alcohol, decocting radix astragali preparata, poria cocos, charred rhubarb, and pulverized pseudo-ginseng, etc. Patent CN101474368A discloses a Chinese medicine for treating age-related macular degeneration, which comprises medlar, dogwood, schisandra chinensis, prepared rehmannia root, weeping forsythia capsule, roasted turtle shell and the like. With the advent of related diagnosis and treatment instruments of ophthalmology, the curative effect of the medicine obtains relatively uniform judgment standards, which provides an effective approved way for developing and utilizing traditional Chinese medicines to treat AMD.
Current dry AMD therapy is directed to preventing and treating AMD, reducing the formation of drusen, and inhibiting the progression of dry AMD to wet AMD. While the most important existing challenges in treating dry AMD are improving visual outcomes, reducing drusen formation and minimizing geographic atrophy. There is some clinical debate as to whether dry AMD intervenes positively. Thus, the present invention provides a pharmaceutical composition for the treatment of dry AMD, which can prevent the visual deterioration of patients and the progression of dry AMD to wet AMD, and can be used as an effective means for the prevention and treatment of dry AMD.
Disclosure of Invention
The inventor combines the medicinal composition for treating the dry AMD according to the etiology and pathogenesis of the AMD based on creative labor and on the basis of disease differentiation and dialectics, and the medicinal composition has the effects of nourishing yin and suppressing yang, removing blood stasis and resolving masses, inducing resuscitation and improving eyesight, walking upper-jiao, guiding medicine upwards, clearing heat and eliminating evil. The pharmaceutical composition is used for treating blurred vision caused by liver-kidney yin deficiency, with symptoms of blurred vision, deformation of vision, dizziness and tinnitus, constipation and abdominal distension, and soreness and weakness of waist and knees; dry age-related macular degeneration (degenerative diseases such as drusen and retinal pigment epithelium atrophy).
In a first aspect of the present invention, there is provided a pharmaceutical composition for the treatment of age-related macular degeneration (AMD), said pharmaceutical composition comprising carapax Trionycis and/or radix Rhodiolae; preferably, the age-related macular degeneration is dry age-related macular degeneration.
Preferably, the pharmaceutical composition comprises turtle shells and rhodiola rosea.
Preferably, the pharmaceutical composition contains 5-15 parts of turtle shell. More preferably, the pharmaceutical composition contains 8-12 parts of turtle shell. More preferably, the pharmaceutical composition comprises 10 parts of turtle shell.
Preferably, the pharmaceutical composition contains 10 to 30 parts of rhodiola rosea. More preferably, the pharmaceutical composition contains 15 to 25 parts of rhodiola rosea. More preferably, the pharmaceutical composition contains 20 parts of rhodiola rosea.
Preferably, the pharmaceutical composition further comprises radix rehmanniae and/or coix seed.
Preferably, the pharmaceutical composition contains 5 to 15 parts of radix rehmanniae. More preferably, the pharmaceutical composition contains 8 to 12 parts of radix rehmanniae. More preferably, the pharmaceutical composition contains 10 parts of radix rehmanniae.
And/or the presence of a gas in the gas,
preferably, the pharmaceutical composition contains 5-15 parts of coix seed. More preferably, the pharmaceutical composition contains 8-12 parts of coix seed. More preferably, the pharmaceutical composition contains 10 parts of coix seeds.
Preferably, the pharmaceutical composition further comprises white paeony root, weeping forsythia and/or cassia seed.
Preferably, the pharmaceutical composition contains 8-20 parts of white paeony root. More preferably, the pharmaceutical composition contains 10-15 parts of white peony root. More preferably, the pharmaceutical composition contains 12 parts of white paeony root.
And/or the presence of a gas in the gas,
preferably, the pharmaceutical composition contains 5-15 parts of fructus forsythiae. More preferably, the pharmaceutical composition contains 8-12 parts of forsythia. More preferably, the pharmaceutical composition contains 10 parts of forsythia.
And/or the presence of a gas in the gas,
preferably, the pharmaceutical composition contains 5-15 parts of cassia seed. More preferably, the pharmaceutical composition contains 8-12 parts of cassia seed. More preferably, the pharmaceutical composition contains 10 parts of cassia seed.
Preferably, the pharmaceutical composition further comprises licorice, and more preferably, the licorice is honey-fried licorice.
Preferably, the pharmaceutical composition contains 5-15 parts of honey-fried licorice root. More preferably, the pharmaceutical composition contains 8-12 parts of honey-fried licorice root. More preferably, the pharmaceutical composition contains 9 parts of honey-fried licorice root.
In one embodiment of the present invention, the pharmaceutical composition comprises carapax Trionycis, radix Rhodiolae and radix rehmanniae.
In one embodiment of the present invention, the pharmaceutical composition comprises carapax Trionycis, radix Rhodiolae, radix rehmanniae and semen Coicis.
In one embodiment of the present invention, the pharmaceutical composition comprises carapax Trionycis, radix Rhodiolae, radix rehmanniae, semen Coicis and radix Paeoniae alba.
In one embodiment of the present invention, the pharmaceutical composition comprises carapax Trionycis, radix Rhodiolae, radix rehmanniae, semen Coicis, radix Paeoniae alba, and fructus forsythiae.
In one embodiment of the present invention, the pharmaceutical composition comprises turtle shell, rhodiola rosea, radix rehmanniae, coix seed, white peony root, forsythia suspense and cassia seed.
In one embodiment of the present invention, the pharmaceutical composition comprises carapax amydae, rhodiola rosea, radix rehmanniae, semen coicis, radix paeoniae alba, fructus forsythiae, semen cassiae and radix glycyrrhizae preparata.
In a specific embodiment of the invention, the pharmaceutical composition comprises 5-15 parts of turtle shell, 10-30 parts of rhodiola rosea and 5-15 parts of radix rehmanniae.
In a specific embodiment of the invention, the pharmaceutical composition comprises 5-15 parts of turtle shell, 10-30 parts of rhodiola rosea, 5-15 parts of radix rehmanniae and 5-15 parts of coix seed.
In a specific embodiment of the invention, the pharmaceutical composition comprises 5-15 parts of turtle shell, 10-30 parts of rhodiola rosea, 5-15 parts of radix rehmanniae, 5-15 parts of coix seed and 8-20 parts of white paeony root.
In a specific embodiment of the invention, the pharmaceutical composition comprises 5-15 parts of turtle shell, 10-30 parts of rhodiola rosea, 5-15 parts of radix rehmanniae, 5-15 parts of coix seed, 8-20 parts of white peony root and 5-15 parts of fructus forsythiae.
In a specific embodiment of the invention, the pharmaceutical composition comprises 5-15 parts of turtle shell, 10-30 parts of rhodiola rosea, 5-15 parts of radix rehmanniae, 5-15 parts of coix seed, 8-20 parts of white peony root, 5-15 parts of fructus forsythiae and 5-15 parts of semen cassiae.
In a specific embodiment of the invention, the pharmaceutical composition comprises 5-15 parts of turtle shell, 10-30 parts of rhodiola rosea, 5-15 parts of radix rehmanniae, 5-15 parts of coix seed, 8-20 parts of white peony root, 5-15 parts of fructus forsythiae, 5-15 parts of semen cassiae and 5-15 parts of honey-fried licorice root.
In another specific embodiment of the invention, the pharmaceutical composition comprises 8-12 parts of turtle shell, 15-25 parts of rhodiola rosea, 8-12 parts of radix rehmanniae, 8-12 parts of coix seed, 10-15 parts of white peony root, 8-12 parts of fructus forsythiae, 8-12 parts of semen cassiae and 8-12 parts of honey-fried licorice root.
In another embodiment of the present invention, the pharmaceutical composition comprises 10 parts of turtle shell, 20 parts of rhodiola rosea, 10 parts of radix rehmanniae, 10 parts of coix seed, 12 parts of white peony root, 10 parts of forsythia, 10 parts of cassia seed and 9 parts of honey-fried licorice root.
Preferably, the pharmaceutical composition also comprises one or the combination of more than two of qi-tonifying drugs, blood-tonifying drugs, yin-tonifying drugs, cold-phlegm-warming and resolving drugs, blood-cooling hemostatics, blood stasis-removing hemostatics, diuresis-inducing and edema-relieving drugs and/or heat-clearing and blood-cooling drugs; wherein the qi tonics are selected from: one or more of radix Ginseng, radix Panacis Quinquefolii, radix Codonopsis, radix Pseudostellariae, radix astragali, rhizoma Atractylodis Macrocephalae, rhizoma Dioscoreae, semen lablab album, fructus Jujubae, radix Et caulis Acanthopanacis Senticosi, gynostemma pentaphyllum, fructus Hippophae, maltose, and Mel; the blood-tonifying agent is selected from: one or more of radix Angelicae sinensis, colla Corii Asini, Polygoni Multiflori radix, arillus longan or fructus Broussonetiae; the yin-tonifying medicine is selected from: radix Glehniae, radix Adenophorae, Bulbus Lilii, radix Ophiopogonis, radix asparagi, herba Dendrobii, rhizoma Polygonati Odorati, rhizoma Polygonati, radix Changii, fructus Lycii, Ecliptae herba, fructus Ligustri Lucidi, Mori fructus, semen Sesami Niger, Tremella, nidus Collocaliae or fish glue; the cold-phlegm warming and resolving medicine is selected from: one or more of rhizoma Pinelliae, rhizoma arisaematis, semen Sinapis Albae, fructus Gleditsiae Abnormalis, Inulae flos, Bulbus Fritillariae Cirrhosae, fructus Trichosanthis, caulis Bambusae in Taenia, succus Bambusae, concretio silicea Bambusae seu Schizostachyi, radix Peucedani, radix Platycodi or semen Scaphii Lychnophori; the blood-cooling hemostatics are selected from: one or more of herba Cephalanoploris, herba seu radix Cirsii Japonici, radix Sangusorbae, flos Sophorae Immaturus, folium Platycladi, lalang grass rhizome, radix Curcumae and radix Boehmeriae; the stasis-removing hemostatics are selected from: one or more of Notoginseng radix, radix Rubiae, pollen Typhae, Ophicalcitum, lignum Dalbergiae Odoriferae and crinis Carbonisatus; the diuresis-inducing and edema-alleviating drug is selected from: poria, Polyporus, Alismatis rhizoma, exocarpium Benincase, stigma Maydis, bottle gourd, cortex Periplocae Radicis, semen Hoveniae, herba Euphorbiae Helioscopiae, Gryllotalpa or herba Capsellae; the heat-clearing and blood-cooling medicine is selected from: charred radix Et rhizoma Rhei, radix scrophulariae, cortex moutan, radix Paeoniae Rubra, radix Arnebiae, cornu Bubali, or herba Rabdosiae Lophanthoidis.
In a second aspect of the invention, a pharmaceutical composition for treating drusen, visual deterioration, retinal pigment epithelium atrophy and/or photoreceptor cell atrophy is provided, wherein the pharmaceutical composition comprises turtle shell and/or rhodiola rosea.
Preferably, the vision deterioration is blurred vision caused by liver-kidney yin deficiency, and the symptoms include blurred vision and deformed vision.
Preferably, the pharmaceutical composition can treat dizziness and tinnitus, constipation and abdominal distension, and soreness and weakness of waist and knees.
Preferably, the pharmaceutical composition comprises turtle shells and rhodiola rosea.
Preferably, the pharmaceutical composition contains 5-15 parts of turtle shell. More preferably, the pharmaceutical composition contains 8-12 parts of turtle shell. More preferably, the pharmaceutical composition comprises 10 parts of turtle shell.
Preferably, the pharmaceutical composition contains 10 to 30 parts of rhodiola rosea. More preferably, the pharmaceutical composition contains 15 to 25 parts of rhodiola rosea. More preferably, the pharmaceutical composition contains 20 parts of rhodiola rosea.
Preferably, the pharmaceutical composition further comprises radix rehmanniae and/or coix seed.
Preferably, the pharmaceutical composition contains 5 to 15 parts of radix rehmanniae. More preferably, the pharmaceutical composition contains 8 to 12 parts of radix rehmanniae. More preferably, the pharmaceutical composition contains 10 parts of radix rehmanniae.
And/or the presence of a gas in the gas,
preferably, the pharmaceutical composition contains 5-15 parts of coix seed. More preferably, the pharmaceutical composition contains 8-12 parts of coix seed. More preferably, the pharmaceutical composition contains 10 parts of coix seeds.
Preferably, the pharmaceutical composition further comprises white paeony root, weeping forsythia and/or cassia seed.
Preferably, the pharmaceutical composition contains 8-20 parts of white paeony root. More preferably, the pharmaceutical composition contains 10-15 parts of white peony root. More preferably, the pharmaceutical composition contains 12 parts of white paeony root.
And/or the presence of a gas in the gas,
preferably, the pharmaceutical composition contains 5-15 parts of fructus forsythiae. More preferably, the pharmaceutical composition contains 8-12 parts of forsythia. More preferably, the pharmaceutical composition contains 10 parts of forsythia.
And/or the presence of a gas in the gas,
preferably, the pharmaceutical composition contains 5-15 parts of cassia seed. More preferably, the pharmaceutical composition contains 8-12 parts of cassia seed. More preferably, the pharmaceutical composition contains 10 parts of cassia seed.
Preferably, the pharmaceutical composition further comprises licorice. More preferably, the licorice is honey-fried licorice.
Preferably, the pharmaceutical composition contains 5-15 parts of honey-fried licorice root. More preferably, the pharmaceutical composition contains 8-12 parts of honey-fried licorice root. More preferably, the pharmaceutical composition contains 9 parts of honey-fried licorice root.
In one embodiment of the present invention, the pharmaceutical composition comprises carapax Trionycis, radix Rhodiolae and radix rehmanniae.
In one embodiment of the present invention, the pharmaceutical composition comprises carapax Trionycis, radix Rhodiolae, radix rehmanniae and semen Coicis.
In one embodiment of the present invention, the pharmaceutical composition comprises carapax Trionycis, radix Rhodiolae, radix rehmanniae, semen Coicis and radix Paeoniae alba.
In one embodiment of the present invention, the pharmaceutical composition comprises carapax Trionycis, radix Rhodiolae, radix rehmanniae, semen Coicis, radix Paeoniae alba, and fructus forsythiae.
In one embodiment of the present invention, the pharmaceutical composition comprises turtle shell, rhodiola rosea, radix rehmanniae, coix seed, white peony root, forsythia suspense and cassia seed.
In one embodiment of the present invention, the pharmaceutical composition comprises carapax amydae, rhodiola rosea, radix rehmanniae, semen coicis, radix paeoniae alba, fructus forsythiae, semen cassiae and radix glycyrrhizae preparata.
In a specific embodiment of the invention, the pharmaceutical composition comprises 5-15 parts of turtle shell, 10-30 parts of rhodiola rosea and 5-15 parts of radix rehmanniae.
In a specific embodiment of the invention, the pharmaceutical composition comprises 5-15 parts of turtle shell, 10-30 parts of rhodiola rosea, 5-15 parts of radix rehmanniae and 5-15 parts of coix seed.
In a specific embodiment of the invention, the pharmaceutical composition comprises 5-15 parts of turtle shell, 10-30 parts of rhodiola rosea, 5-15 parts of radix rehmanniae, 5-15 parts of coix seed and 8-20 parts of white paeony root.
In a specific embodiment of the invention, the pharmaceutical composition comprises 5-15 parts of turtle shell, 10-30 parts of rhodiola rosea, 5-15 parts of radix rehmanniae, 5-15 parts of coix seed, 8-20 parts of white peony root and 5-15 parts of fructus forsythiae.
In a specific embodiment of the invention, the pharmaceutical composition comprises 5-15 parts of turtle shell, 10-30 parts of rhodiola rosea, 5-15 parts of radix rehmanniae, 5-15 parts of coix seed, 8-20 parts of white peony root, 5-15 parts of fructus forsythiae and 5-15 parts of semen cassiae.
In a specific embodiment of the invention, the pharmaceutical composition comprises 5-15 parts of turtle shell, 10-30 parts of rhodiola rosea, 5-15 parts of radix rehmanniae, 5-15 parts of coix seed, 8-20 parts of white peony root, 5-15 parts of fructus forsythiae, 5-15 parts of semen cassiae and 5-15 parts of honey-fried licorice root.
In another specific embodiment of the invention, the pharmaceutical composition comprises 8-12 parts of turtle shell, 15-25 parts of rhodiola rosea, 8-12 parts of radix rehmanniae, 8-12 parts of coix seed, 10-15 parts of white peony root, 8-12 parts of fructus forsythiae, 8-12 parts of semen cassiae and 8-12 parts of honey-fried licorice root.
In another embodiment of the present invention, the pharmaceutical composition comprises 10 parts of turtle shell, 20 parts of rhodiola rosea, 10 parts of radix rehmanniae, 10 parts of coix seed, 12 parts of white peony root, 10 parts of forsythia, 10 parts of cassia seed and 9 parts of honey-fried licorice root.
Preferably, the pharmaceutical composition also comprises one or the combination of more than two of qi-tonifying drugs, blood-tonifying drugs, yin-tonifying drugs, cold-phlegm-warming and resolving drugs, blood-cooling hemostatics, blood stasis-removing hemostatics, diuresis-inducing and edema-relieving drugs and/or heat-clearing and blood-cooling drugs; wherein the qi tonics are selected from: one or more of radix Ginseng, radix Panacis Quinquefolii, radix Codonopsis, radix Pseudostellariae, radix astragali, rhizoma Atractylodis Macrocephalae, rhizoma Dioscoreae, semen lablab album, fructus Jujubae, radix Et caulis Acanthopanacis Senticosi, gynostemma pentaphyllum, fructus Hippophae, maltose, and Mel; the blood-tonifying agent is selected from: one or more of radix Angelicae sinensis, colla Corii Asini, Polygoni Multiflori radix, arillus longan or fructus Broussonetiae; the yin-tonifying medicine is selected from: radix Glehniae, radix Adenophorae, Bulbus Lilii, radix Ophiopogonis, radix asparagi, herba Dendrobii, rhizoma Polygonati Odorati, rhizoma Polygonati, radix Changii, fructus Lycii, Ecliptae herba, fructus Ligustri Lucidi, Mori fructus, semen Sesami Niger, Tremella, nidus Collocaliae or fish glue; the cold-phlegm warming and resolving medicine is selected from: one or more of rhizoma Pinelliae, rhizoma arisaematis, semen Sinapis Albae, fructus Gleditsiae Abnormalis, Inulae flos, Bulbus Fritillariae Cirrhosae, fructus Trichosanthis, caulis Bambusae in Taenia, succus Bambusae, concretio silicea Bambusae seu Schizostachyi, radix Peucedani, radix Platycodi or semen Scaphii Lychnophori; the blood-cooling hemostatics are selected from: one or more of herba Cephalanoploris, herba seu radix Cirsii Japonici, radix Sangusorbae, flos Sophorae Immaturus, folium Platycladi, lalang grass rhizome, radix Curcumae and radix Boehmeriae; the stasis-removing hemostatics are selected from: one or more of Notoginseng radix, radix Rubiae, pollen Typhae, Ophicalcitum, lignum Dalbergiae Odoriferae and crinis Carbonisatus; the diuresis-inducing and edema-alleviating drug is selected from: poria, Polyporus, Alismatis rhizoma, exocarpium Benincase, stigma Maydis, bottle gourd, cortex Periplocae Radicis, semen Hoveniae, herba Euphorbiae Helioscopiae, Gryllotalpa or herba Capsellae; the heat-clearing and blood-cooling medicine is selected from: charred radix Et rhizoma Rhei, radix scrophulariae, cortex moutan, radix Paeoniae Rubra, radix Arnebiae, cornu Bubali, or herba Rabdosiae Lophanthoidis.
The turtle shell and the rhodiola rosea in the pharmaceutical composition are monarch drugs and have the effects of tonifying qi and nourishing blood, nourishing yin and suppressing yang, and inhibiting fusion of a glass membrane and breeding of new blood vessels.
The rehmannia root and coix seed in the medicinal composition are ministerial medicaments, and have the effects of nourishing yin and blood, assisting turtle shells in clearing heat, eliminating phlegm and softening hard masses, and clearing away deposit metabolites in macular regions.
The white paeony root, the weeping forsythia and the cassia seed in the medicine composition are adjuvant medicines, the three medicines of astringing, clearing and dispersing are combined to clear heat of upper jiao, and the medicine composition is a good medicine for treating eye diseases.
The honey-fried licorice root in the pharmaceutical composition is a guiding drug, and can regulate the effects of the drugs in the recipe, and also can be matched with the white paeony root for acid and sweet taste to transform yin and regulate the liver and spleen.
In a third aspect of the present invention, there is provided a method for preparing the pharmaceutical composition of the first or second aspect, wherein the method is selected from solvent extraction, percolation, decoction, reflux, continuous reflux, ultrasonic extraction, supercritical fluid extraction, steam distillation, sublimation, resin adsorption separation or gel chromatography.
In a specific embodiment of the present invention, the preparation method of the pharmaceutical composition of the first aspect or the second aspect is a water decoction method, which comprises the following steps:
1) weighing the medicines according to the formula of the medicinal composition, and placing the medicines into a decocting device with a proper volume;
2) adding water capable of immersing the medicine, boiling and heating after immersing;
3) separating the decoctions, decocting the residues, and mixing the decoctions;
4) measuring the volume of the decoction, concentrating to the required volume, and storing for later use.
Preferably, the immersion time in the step 2) is 0.5-1.5 h.
More preferably, the immersion time in the step 2) is 0.8-1.2 h.
Preferably, the heating time in the step 2) is 0.3-1.2 h.
More preferably, the heating time in the step 2) is 0.5-1.0 h.
In a fourth aspect of the invention, there is provided a method of treating AMD comprising administering a pharmaceutical composition according to the invention.
In a fifth aspect of the invention, there is provided a method of treating drusen, vision loss, retinal pigment epithelium atrophy and/or photoreceptor cell atrophy comprising administering a pharmaceutical composition according to the invention.
Drawings
Embodiments of the invention are described in detail below with reference to the attached drawing figures, wherein:
FIG. 1: OCT images before treatment and after 3 months and 6 months of treatment. Wherein (A) is before treatment, macular fovea drusen can be seen, and RPE changes; (B) after 3 months of treatment, the number and the range of drusen are reduced compared with those before treatment. (C) After 6 months of treatment, the number and scope of drusen was further reduced.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only some embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
EXAMPLE 1 preparation of pharmaceutical composition
1) The formula of the pharmaceutical composition comprises:
10g of turtle shell, 20g of rhodiola rosea, 10g of radix rehmanniae, 10g of coix seed, 12g of white paeony root, 10g of fructus forsythiae, 10g of cassia seed and 9g of honey-fried licorice root.
2) Preparation method
Weighing the medicines according to the formula, mixing, putting into a decocting device with a proper volume, adding about 600mL of water to immerse the medicines for 1h, boiling and heating for 0.5 h. Separating the decoction, decocting the residues twice, mixing the decoction with the first decoction, measuring the volume with a measuring cylinder, further boiling and concentrating the decoction to about 600mL if the volume exceeds 600mL, and storing the decoction at 4 ℃ after the corresponding volume is reached.
EXAMPLE 2 preparation of pharmaceutical composition
1) The formula of the pharmaceutical composition comprises:
5g of turtle shell, 30g of rhodiola rosea, 15g of radix rehmanniae, 5g of coix seed, 8g of white paeony root, 15g of weeping forsythia, 5g of cassia seed and 5g of honey-fried licorice root.
2) Preparation method
Weighing the medicines according to the formula, mixing, putting into a decocting device with a proper volume, adding about 600mL of water to immerse the medicines for 1h, boiling and heating for 0.5 h. Separating the decoction, decocting the residues twice, mixing the decoction with the first decoction, measuring the volume with a measuring cylinder, further boiling and concentrating the decoction to about 600mL if the volume exceeds 600mL, and storing the decoction at 4 ℃ after the corresponding volume is reached.
EXAMPLE 3 preparation of pharmaceutical composition
1) The formula of the pharmaceutical composition comprises:
15g of turtle shell, 10g of rhodiola rosea, 5g of radix rehmanniae, 15g of coix seed, 20g of white paeony root, 5g of fructus forsythiae, 15g of cassia seed and 15g of honey-fried licorice root.
2) Preparation method
Weighing the medicines according to the formula, mixing, putting into a decocting device with a proper volume, adding about 600mL of water to immerse the medicines for 1h, boiling and heating for 0.5 h. Separating the decoction, decocting the residues twice, mixing the decoction with the first decoction, measuring the volume with a measuring cylinder, further boiling and concentrating the decoction to about 600mL if the volume exceeds 600mL, and storing the decoction at 4 ℃ after the corresponding volume is reached.
Example 4 case study
The pharmaceutical composition provided by the invention has proved the effectiveness in clinic for many times. The pharmaceutical composition is used for treating 32 dry AMD (32 eyes) from 1 month to 2017 months in 2015, the influence of the dry AMD on the fundus is observed, and a certain clinical curative effect is obtained after 6 months of treatment by taking optimal corrected vision, color fundus photography, Fundus Fluorography (FFA) and Optical Coherence Tomography (OCT) as curative effect indexes, and the report is given below.
1. Source of study case
The observed cases were all from the ophthalmology clinic of beijing central friendly hospital, 7 months 2014 to 12 months 2017, and were diagnosed as patients with dry AMD by Optical Coherence Tomography (OCT) and Fluorescein Fundus Angiography (FFA).
2. Diagnostic criteria for study cases
Dry AMD is confirmed by reference to Western diagnostic standards for exudative AMD (according to ophthalmology 2) in combination with color fundus photography, OCT, FFA detection and clinical symptoms at outpatient sites.
Dry AMD diagnostic criteria:
(1) the disease occurs in one eye or two eyes simultaneously, and the vision is slowly reduced;
(2) the early stage of the eyeground is mostly scattered on drusen;
(3) at late stages, the geographic pigment epithelium atrophy, revealing gross choroidal vessels.
2.1 case inclusion criteria
(1) At least one eye meets the Western diagnosis standard of age-related macular degeneration and is clinically a patient with dry AMD;
(2) age 45-80 years (including 45 and 80 years);
(3) drusen exist under and beside the fovea centralis;
(4) the refraction interstitium is basically clear, and does not obstruct the fundus examination and the fundus blood vessel fluorography;
(5) the patients had good compliance with the observation and efficacy evaluation of the study;
(6) no other clinical trials were enrolled for 2-4 weeks prior to treatment.
2.2 case exclusion criteria
(1) Combined with ocular fundus diseases such as high myopia, glaucoma, diabetic retinopathy, retinal artery and vein occlusion, optic neuropathy (optic neuritis, atrophy, papilledema), macular hole, etc., and affecting the eyesight;
(2) eyeground ametropia with unclear interstitium (such as vitreous hemorrhage and cataract) affects observers of eyeground conditions;
(3) complicated with severe cardiovascular and cerebrovascular diseases, liver, kidney and hematopoietic system disorders; psychotic patients;
(4) patients who do not complete the required normative treatment;
(5) those who are severely allergic to sodium fluorescein needles;
(6) patients who are participating in other drug clinical trials; patients who use the same kind of traditional Chinese medicine and other treatments together; or a midway quit; or the subject is reluctant to participate in the clinical trial.
3. Research method
3.1 test grouping
One eye (1 eye was randomly selected from the patients with both eyes) was taken as the study subject, and all the patients were divided into 30 patients (30 eyes) in the treatment group and 29 patients (29 eyes) in the control group by the random number table method. Wherein 17 men and 13 women in the treatment group are 71.37 + -7.24 years of mean age and 56-82 years of age; the average course of disease is 37.80 +/-35.61 months, and the range of the course of disease is 6-144 months. Wherein 15 cases of men and 14 cases of women have the average age of 70.90 +/-6.82 years and the age range of 56-80 years; the average course of disease is 40.03 +/-38.13 months, the range of the course of disease is 4-138 months, and the two groups have no statistical difference in the composition ratio, age and course of disease of men and women and have comparability.
3.2 therapeutic Agents
Treatment groups: dry AMD patients meeting inclusion criteria were treated with the pharmaceutical composition formulation of example 1. The prescription is composed of 8 traditional Chinese medicines such as turtle shell, rhodiola rosea, radix rehmanniae, cassia seed, coix seed, forsythia, white paeony root, honey-fried licorice root and the like. The water decoction provided by the pharmacy department of the Zhongri friendly hospital is taken once a day, 200mL of the water decoction is taken twice in the morning and at night, and the water decoction is continuously taken for 3 months.
Control group: administering vitamin C tablets 0.2g each time for 3 times per day to dry AMD patients meeting inclusion criteria, and orally administering; vitamin E tablet is administered orally 0.1g each time and 3 times a day. The curative effect is counted after continuously taking the medicine for 3 months.
3.3 evaluation index and judgment Standard of therapeutic Effect
The patients underwent general ophthalmic examination (visual acuity, intraocular pressure, slit-lamp examination, direct ophthalmoscopy) and OCT examination before and after 1, 3, and 6 months of treatment, and underwent fundus color photography and FFA examination before and after 6 months of treatment.
(1) Best Corrected Visual Acuity (BCVA) test: the visual acuity test chart (ETDRS) was studied using early diabetic retinopathy and examined after wearing best correcting lenses. Performing initial vision examination at a position of 4 meters, enabling a patient to read the number of letters from the first row above the visual chart, performing reading of the next row if the number of the letters read in each row is more than or equal to 4, and stopping examination if not; when the number of the letters which can be correctly read by the patient at the position of 4 meters is more than or equal to 4, the distance does not need to be changed, if the requirement is not met, the patient needs to move to the position of 1 meter for examination, a +0.75 sphere lens is added to compensate the shortening of the distance, and only the first 6 rows of 30 letters are read. If the number of correctly recognized letters at 1 meter is 0, recording as follows: light or no light. After the examination is finished according to the program, the total number N of the letters correctly read by the tested person at all the testing distances is calculated, and the N is the vision score. The calculation method is as follows: only at 4 meters check, N equals the number of letters correctly read at 4 meters plus 30; if there is a check from 4 meters to 1 meter, N is equal to the number of correctly read letters at 4 meters plus the number of correctly read letters at l meters.
(2) Fovea maculata thickness: after giving a sufficient mydriasis to a patient, a linear scan is performed in a multi-azimuth radial manner with 6mm length on the most prominent part of the lesion, and the thickness of the fovea maculata (CMT) (the distance from the lowest point of the inner surface of the retina to the inner boundary of the retinal pigment epithelial cell layer) is measured using 3D OCT2000(Topcon corporation, japan), and after the treatment, the CMT is measured by taking the same direction linear scan and measuring the position.
(3) Amsler Table: before and after treatment, the eyes are tested once, the eyes are worn with corrective glasses under natural light, and the square lines are observed under the natural pupils at the center of the fixation chart. The effect is shown: the Amsler table checks that the reduction of the number of normal or abnormal lattices is more than or equal to 10 lattices; the number of abnormal lattices is reduced by more than or equal to 5 lattices and less than 10 lattices in effective table check; the invalid table checks for a decrease or increase in the number of exception grids.
(4) The central visual field program perimeter is a projection type hemisphere perimeter, a macular lesion visual field detection program is selected, examination is carried out once before and after treatment, and the change of the visual field is observed. The effect is shown: the reduction of the central dark point is more than or equal to 50(ii) a The effective central dark spot is reduced to be more than or equal to 50(ii) a And (4) invalidation: the central dark spot shrinks or enlarges.
4. Statistical analysis
All data results were processed with SPSS statistics17.0 statistical software, and the data were measured as means. + -. SD
The comparison between two samples adopts independent sample t test, if the data before and after treatment are normally distributed, the paired sample t test is adopted, and the counting data adopts X test2Testing, if the distribution is abnormal, adopting wilcoxon test, and using P<A difference of 0.05 is statistically significant.
5 results
5.1 changes in eyesight
For vision detection, an EDTRS visual chart is adopted for detection, and the vision is checked after the best correction lens is worn. The letter numbers of the vision before treatment and after treatment at 3 rd and 6 th months are respectively 64.77 +/-9.78, 67.93 +/-8.71 and 69.07 +/-8.70, the letter numbers of the vision before treatment and after treatment at 3 rd and 6 th months are respectively 63.69 +/-7.13, 65.07 +/-8.43 and 65.9 +/-8.07 in the control group, and compared with the vision before treatment and after treatment at 3 rd and 6 th months, the vision of the two groups is obviously improved (P is less than 0.05, see table 1). However, after 6 months of treatment, there was a significant improvement in the vision of the treated group compared to before treatment (P <0.05, see table 1). The treatment group mean EDTRS letter number increased significantly from 64.77 ± 9.78 before treatment to 69.07 ± 8.70 after 6 months of treatment. The mean EDTRS letter number of the control group increased from 63.69 ± 7.13 before treatment to 65.9 ± 8.07 after 6 months of treatment with no significant difference compared to before treatment (P > 0.05).
TABLE 1 comparison of best corrected Vision (EDTRS letters) before and after 3 and 6 months of treatment
Note: compared with the method before the treatment,*P<0.05; compared with the control group, the method has the advantages that,#P<0.05。
5.2 changes in CMT
To determine changes in retinal macular anatomy, a reliable measurement was made of the CMT of 59 cases (59 eyes). After the treatment with the pharmaceutical composition and the vitamins, the CMT is reduced, and compared with the CMT before the treatment, the CMT is obviously reduced after 3 and 6 months of treatment (P is less than 0.05, see table 2 and figure 1). In the treatment group, compared with 239.08 + -25.99 μm (range 179-298 μm) before treatment, the difference is significant when 191.18 + -47.45 μm (range 143-211 μm) of CMT is reduced by 47.9 μm on average after 6 months of treatment. The CMT decreased 6 months after vitamin C and vitamin E treatment in the control group compared to before treatment (P <0.05, see table 2), but no significant difference was seen 3 months later (P > 0.05). There was no statistical significance between the two groups compared before and after treatment. FIG. 1 is a graph of the change in CMT before treatment and after 3 and 6 months of treatment, as seen in the OCT graph of FIG. 1 (A) before treatment, drusen of the macular center fovea, changes in RPE are seen; (B) after 3 months of treatment, the number and the range of drusen are reduced compared with those before treatment. (C) After 6 months of treatment, the number and scope of drusen was further reduced.
TABLE 2 comparison of CMT between the two groups before and after 3 and 6 months of treatment
Note: compared with the method before the treatment,*P<0.05; compared with the control group, the method has the advantages that,#P<0.05。
5.3 variation of the conditions of the Amsler Table
As shown in table 3, after 6 months of treatment, the number of eyes reaching "significant effect" in the treatment group was 7, the number of eyes reaching "significant effect" was 19, the total effective rate was 86.66%, the number of eyes reaching "significant effect" in the control group was 5, the number of eyes reaching "significant effect" was 14, the total effective rate was 65.52%, the difference between the two groups was statistically significant (P <0.05, see table 3), and the Amsler table condition of the treatment group was superior to that of the control group.
TABLE 3 comparison of the conditions of the two Amsler tables
5.4 change in field of view
As shown in table 4, after 6 months of treatment, the number of eyes reaching "significant effect" in the treatment group was 5, the number of eyes reaching "significant effect" was 18, the total effective rate was 76.67%, the number of eyes reaching "significant effect" in the control group was 3, the number of eyes reaching "significant effect" was 10, the total effective rate was 44.83%, the two groups were compared, the difference had statistical significance (P <0.05, table 4), and the visual field change condition of the treatment group was superior to that of the control group.
TABLE 4 comparison of two groups of visual field conditions
Compared with the prior treatment, the Amsler surface condition and the visual field change condition after the treatment by using the pharmaceutical composition with the formula in the example 1 are improved, and the 'ineffective' percentages of the Amsler surface condition and the visual field change condition after 6 months of treatment are respectively 13.34 percent and 23.33 percent, which shows that the drusen formation in a macular region is inhibited, and the local hypoxia-ischemia state is improved, which is one advantage of the pharmaceutical composition for treatment. Compared with the existing method without effective treatment, the pharmaceutical composition has special application and research value in treating the intractable eye disease.
The preferred embodiments of the present invention have been described in detail, however, the present invention is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present invention within the technical idea of the present invention, and these simple modifications are within the protective scope of the present invention.
It should be noted that the various technical features described in the above embodiments can be combined in any suitable manner without contradiction, and the invention is not described in any way for the possible combinations in order to avoid unnecessary repetition.
Claims (10)
1. A pharmaceutical composition for treating age-related macular degeneration is characterized by comprising turtle shells and/or rhodiola rosea.
2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises carapax trionycis and rhodiola rosea, wherein the pharmaceutical composition comprises 5-15 parts of carapax trionycis, and the pharmaceutical composition comprises 10-30 parts of rhodiola rosea.
3. The pharmaceutical composition according to claim 1 or 2, further comprising radix rehmanniae and/or semen coicis, wherein the pharmaceutical composition comprises 5-15 parts of radix rehmanniae and/or the pharmaceutical composition comprises 5-15 parts of semen coicis.
4. The pharmaceutical composition of any one of claims 1-3, further comprising radix Paeoniae alba, fructus forsythiae and/or semen Cassiae, wherein the pharmaceutical composition comprises 8-20 parts of radix Paeoniae alba, 5-15 parts of fructus forsythiae and/or 5-15 parts of semen Cassiae.
5. The pharmaceutical composition according to any one of claims 1 to 4, further comprising licorice, wherein the pharmaceutical composition comprises 5 to 15 parts of licorice.
6. The pharmaceutical composition of any one of claims 1-5, wherein said pharmaceutical composition comprises carapax Trionycis, radix Rhodiolae, radix rehmanniae, semen Coicis, radix Paeoniae alba, fructus forsythiae, semen Cassiae, and radix Glycyrrhizae.
7. The pharmaceutical composition of claim 6, wherein the pharmaceutical composition comprises 5-15 parts of turtle shell, 10-30 parts of rhodiola rosea, 5-15 parts of radix rehmanniae, 5-15 parts of coix seed, 8-20 parts of white peony root, 5-15 parts of fructus forsythiae, 5-15 parts of semen cassiae and 5-15 parts of liquorice.
8. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition comprises 10 parts of turtle shell, 20 parts of rhodiola rosea, 10 parts of radix rehmanniae, 10 parts of coix seed, 12 parts of white peony root, 10 parts of forsythia, 10 parts of cassia seed and 9 parts of licorice.
9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the pharmaceutical composition further comprises one or a combination of more than two of qi tonics, blood tonics, yin tonics, cold-phlegm-warming and resolving herbs, blood-cooling hemostatics, blood stasis-removing hemostatics, edema-alleviating diuretics and/or heat-clearing and blood-cooling herbs; wherein the qi tonics are selected from: one or more of radix Ginseng, radix Panacis Quinquefolii, radix Codonopsis, radix Pseudostellariae, radix astragali, rhizoma Atractylodis Macrocephalae, rhizoma Dioscoreae, semen lablab album, fructus Jujubae, radix Et caulis Acanthopanacis Senticosi, gynostemma pentaphyllum, fructus Hippophae, maltose, and Mel; the blood-tonifying agent is selected from: one or more of radix Angelicae sinensis, colla Corii Asini, Polygoni Multiflori radix, arillus longan or fructus Broussonetiae; the yin-tonifying medicine is selected from: radix Glehniae, radix Adenophorae, Bulbus Lilii, radix Ophiopogonis, radix asparagi, herba Dendrobii, rhizoma Polygonati Odorati, rhizoma Polygonati, radix Changii, fructus Lycii, Ecliptae herba, fructus Ligustri Lucidi, Mori fructus, semen Sesami Niger, Tremella, nidus Collocaliae or fish glue; the cold-phlegm warming and resolving medicine is selected from: one or more of rhizoma Pinelliae, rhizoma arisaematis, semen Sinapis Albae, fructus Gleditsiae Abnormalis, Inulae flos, Bulbus Fritillariae Cirrhosae, fructus Trichosanthis, caulis Bambusae in Taenia, succus Bambusae, concretio silicea Bambusae seu Schizostachyi, radix Peucedani, radix Platycodi or semen Scaphii Lychnophori; the blood-cooling hemostatics are selected from: one or more of herba Cephalanoploris, herba seu radix Cirsii Japonici, radix Sangusorbae, flos Sophorae Immaturus, folium Platycladi, lalang grass rhizome, radix Curcumae and radix Boehmeriae; the stasis-removing hemostatics are selected from: one or more of Notoginseng radix, radix Rubiae, pollen Typhae, Ophicalcitum, lignum Dalbergiae Odoriferae and crinis Carbonisatus; the diuresis-inducing and edema-alleviating drug is selected from: poria, Polyporus, Alismatis rhizoma, exocarpium Benincase, stigma Maydis, bottle gourd, cortex Periplocae Radicis, semen Hoveniae, herba Euphorbiae Helioscopiae, Gryllotalpa or herba Capsellae; the heat-clearing and blood-cooling medicine is selected from: charred radix Et rhizoma Rhei, radix scrophulariae, cortex moutan, radix Paeoniae Rubra, radix Arnebiae, cornu Bubali, or herba Rabdosiae Lophanthoidis.
10. A process for the preparation of a pharmaceutical composition according to any one of claims 1 to 9, wherein said process is selected from the group consisting of solvent extraction, percolation, decoction, reflux, ultrasonic extraction and supercritical fluid extraction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910698934.XA CN112294963B (en) | 2019-07-31 | 2019-07-31 | Pharmaceutical composition for treating age-related macular degeneration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910698934.XA CN112294963B (en) | 2019-07-31 | 2019-07-31 | Pharmaceutical composition for treating age-related macular degeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112294963A true CN112294963A (en) | 2021-02-02 |
| CN112294963B CN112294963B (en) | 2024-06-28 |
Family
ID=74485957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910698934.XA Active CN112294963B (en) | 2019-07-31 | 2019-07-31 | Pharmaceutical composition for treating age-related macular degeneration |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112294963B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023035950A1 (en) * | 2021-09-13 | 2023-03-16 | 珠海岐微生物科技有限公司 | Method for treating retinal degeneration |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474368A (en) * | 2008-11-28 | 2009-07-08 | 安徽省药物研究所 | Chinese medicine for treating macular degeneration related to age and preparation method |
-
2019
- 2019-07-31 CN CN201910698934.XA patent/CN112294963B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474368A (en) * | 2008-11-28 | 2009-07-08 | 安徽省药物研究所 | Chinese medicine for treating macular degeneration related to age and preparation method |
Non-Patent Citations (3)
| Title |
|---|
| 吴晓阳: "中药治疗老年性黄斑变性43例", 湖北中医杂志, vol. 32, no. 9, pages 52 - 53 * |
| 宋威等: "老年黄斑变性的中西医治疗概况", 广州中医药大学学报, vol. 25, no. 4, pages 374 - 376 * |
| 我是雷锋: "眼部黄斑病变", pages 3, Retrieved from the Internet <URL:https://wiki.pclady.com.cn/wap/wiki/g4z41436.html> * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023035950A1 (en) * | 2021-09-13 | 2023-03-16 | 珠海岐微生物科技有限公司 | Method for treating retinal degeneration |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112294963B (en) | 2024-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102600386B (en) | Chinese herba preparation for treating eye inflammation and preparation method of Chinese herba preparation | |
| CN108992544A (en) | A kind of Chinese medicine composition for preventing and treating eye disease | |
| CN102885975B (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN112294963B (en) | Pharmaceutical composition for treating age-related macular degeneration | |
| CN105055785B (en) | A kind of Chinese medicine composition for treating diabetic retinopathy | |
| CN109865016A (en) | A kind of pharmaceutical composition and its preparation method and application for treating xerophthalmia | |
| CN104147180A (en) | Medicine composition for treating immune thrombocytopenic purpura and preparation method thereof | |
| CN104740334B (en) | It is a kind of to be used to prevent and treat Chinese medicine composition of cataract and preparation method thereof | |
| CN107648397B (en) | Traditional Chinese medicine composition for treating liver-kidney yin deficiency and preparation method and application thereof | |
| CN112121104A (en) | Traditional Chinese medicine composition for relieving asthenopia and preventing and treating myopia | |
| CN102210841A (en) | Chinese medicinal preparation for treating central serous retinopathy | |
| CN110179966A (en) | The preparation method and applications of traditional Chinese medicine composition for relieving asthenopia | |
| CN104324139B (en) | A kind of pharmaceutical composition treating xerophthalmia | |
| CN104096153A (en) | Pharmaceutical composition containing multiple plant active ingredients and preparation method and application thereof | |
| CN109663100A (en) | A kind of Chinese medicine composition and its preparation method and application for treating optic neuritis | |
| CN108991364A (en) | A kind of black pine novel foodstuff and preparation method thereof | |
| CN113304234B (en) | Traditional Chinese medicine composition for treating chronic renal failure | |
| CN108635420B (en) | A Chinese medicinal composition for treating nephritis and its extract | |
| CN105395710A (en) | Folium artemisiae argyi-containing traditional Chinese medicine preparation for treating fundus hemorrhage and preparing method thereof | |
| CN105833064A (en) | Eyesight-improving decoction for treating diabetic retinopathy | |
| CN109105732A (en) | A kind of alleviation visual fatigue rice paste and preparation method thereof | |
| CN104800465A (en) | Traditional Chinese medicine composition for treating stagnation of qi due to depression of liver type primary glaucoma | |
| CN115737725A (en) | Traditional Chinese medicine composition for treating xerophthalmia and preparation method thereof | |
| CN105726939A (en) | Folium artemisiae argyi containing medicine composition for treating diabetic retinopathy | |
| CN104771473B (en) | A kind of Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |